A full-term neonate is reported with congenital cystic adenomatoid malformation of the lung treated by lobectomy with development of pulmonary hypertension. The infant was successfully treated with extracorporeal membrane oxygenation (ECMO) for persistent pulmonary hypertension, which developed postoperatively. An 18-day course of venovenous ECMO was necessary to effectively reverse the severe pulmonary hypertension. This was probably a result of significant pulmonary hypoplasia of the compressed lung. Although not all congenital cystic adenomatoid malformations of the lung are associated with pulmonary hypoplasia and persistent pulmonary hypertension, this is one case where severe pulmonary hypertension developed secondary to a mass effect by a large lesion in the chest.
A full-term neonate is reported with congenital cystic adenomatoid malformation of the lung treated by lobectomy with development of pulmonary hypertension. The infant was successfully treated with extracorporeal membrane oxygenation (ECMO) for persistent pulmonary hypertension, which developed postoperatively. An 18-day course of venovenous ECMO was necessary to effectively reverse the severe pulmonary hypertension. This was probably a result of significant pulmonary hypoplasia of the compressed lung. Although not all congenital cystic adenomatoid malformations of the lung are associated with pulmonary hypoplasia and persistent pulmonary hypertension, this is one case where severe pulmonary hypertension developed secondary to a mass effect by a large lesion in the chest.
Persistent pulmonary hypertension (PPHN) may complicate the clinical course in newborns with space occupying thoracic lesions such as congenital diaphragmatic hernia and pulmonary cystic disease. The pathophysiology is related to a mass effect on the adjacent lung and the development of secondary pulmonary hypoplasia during fetal life. Pulmonary hypertension is produced primarily by the reduced size and number of the pulmonary arteries, with further contribution made by increased muscularization of the pulmonary arterial bed and increased reactivity of the pulmonary vessels to vasoconstrictive stimuli. We are reporting a case of congenital cystic adenomatoid malformation (CCAM) of the lung, where pulmonary hypertension developing after lobectomy was successfully treated with prolonged use of extracorporeal membrane oxygenation (ECMO).
Case Report
The infant was a 3230-gm white male born at 38 weeks' gestation via spontaneous vaginal delivery to a 26-year-old gravida 3, para 3, aborta 0 mother. Pregnancy was complicated by polyhydramnios. Apgar scores were 5 and 7 at 1 and 5 minutes, respectively. The infant developed severe respiratory distress soon after birth and required assisted ventilation and transfer to the Neonatal Intensive Care Unit at the Medical University of South Carolina Children's Hospital for further care. The initial chest radiograph, was significant for bilateral diffuse patchy infiltrates with air bronchogram and questionable right pulmonary mass effect. The infant received three doses of beractant (Survanta; Ross Laboratories, Columbus, OH) but showed no improvement in oxygenation and ventilation. On conventional mechanical ventilation (CMV) at FIO-2 1.0, rate of 60 per minute and Paw of 13.7 cm H 2 O, the postductal arterial blood gas was pH 7.24, PaCO 2 61 mm Hg, and PaO 2 60 mm Hg. The pre-and postductal pulse oxygen saturations were 95% and 93%, respectively. High-frequency jet ventilation (HFJV) was initiated because of hypercarbia. A follow-up chest radiograph demonstrated a focal area of nonhomogeneous opacity in the right mid and lower thorax, which was highly suggestive of a right pulmonary mass. There was hyperinflation of the remaining right lung with mediastinal shift and total lung collapse on the left ( Figure  1) . A two-dimensional and Doppler echocardiogram showed a patent foramen ovale with left-to-right shunt and a small patent ductus arteriosus that was restrictive with a 6-mm Hg gradient left-to-right shunt. This suggested near systemic pulmonary arterial pressure. Trivial tricuspid insufficiency (the inability to obtain accurate gradient), trivial aortic insufficiency, and normal left ventricular size and function were also demonstrated. An ultrasound examination of the chest demonstrated a right-sided solid lung mass that was about 4 cm in length and 2 cm in depth, but without echolucent areas (Figure 2 ). Doppler tracings showed very high end-diastolic flow into the mass. No large blood vessels could be identified from the aorta below the diaphragm to the mass, thereby excluding broncho-pulmonary se-
questration. 1 No other congenital anomalies were found. The differential diagnosis at this point included CCAM of the lung or a solid pulmonary tumor. The infant underwent surgery at 72 hours of age. Prior to surgery, the infant was switched to CMV.
A right posterior-lateral thoracotomy was performed, and the infant was found to have only two anatomical right pulmonary lobes.
The right upper and middle lobes were fused into a single large lobe. A large mass was identified in the center of the two fused lobes. Resection of the fused lobes containing the pulmonary lesion was performed. The remaining lobe (right lower lobe of the lung) was found to be small and hypoplastic. The left lung was significantly compressed. Pathologic examination demonstrated multiple small, uniform cysts, ranging from 0.1 to 1.0 cm in maximum dimension and giving the lung tissue a solid appearance. The cysts were made up of low-cuboidal epithelial lining, thin and smooth muscular wall (Յ50-m thickness), and some mucus cells present in a pattern reminiscent of gastric epithelium. No cartilage or skeletal muscle was identified within the lesion. The pulmonary status made ventilatory management under anesthesia difficult, and the patient developed hypoxemia (PaO 2 of 40 mm Hg) and hypercarbia (PaCO 2 Յ100 mm Hg). However, after removal of the affected lobes, ventilation of the left lung improved significantly.
Postoperatively, the infant was placed back on HFJV because of hypercarbia with a PaCO 2 as high as 119 mm Hg on CMV. For a 4-hour period, the best postductal arterial blood gas was pH 7.38, the PaCO 2 was 55 mm Hg, the PaO 2 was 276 mm Hg at FIO 2 1.0, the HFJV rate was 8 Hz, the back-up CMV rate was 10 per minute, and the Paw was 13.9 cm H 2 O. For the next 6 days the neonate remained stable on HFJV with PaO 2 varying between 67 and 288 mm Hg. On postoperative day 7, the infant acutely deteriorated with a PaO 2 of Ͻ50 mm Hg, and the oxygenation index (Paw ϫ FIO 2 ϫ 100/postductal PaO 2 ) increased to 40. Postductal arterial blood gas was pH 7.12, PaCO 2 84 mm Hg, PaO 2 22 mm Hg. A two-dimensional and Doppler echocardiogram demonstrated significant pulmonary hypertension with tricuspid insufficiency and a suprasystemic right ventricular pressure of approximately 90 mm Hg (estimated by using the tricuspid valve insufficiency jet, and the modified Bernoulli equation with an assumed right atrial pressure of 6 mm Hg). There was no improvement in oxygenation in a 4-hour period, and veno-venous ECMO was therefore instituted at 192 hours of age by operative placement of a 12-French double-lumen cannula ( Jostra USA, Austin, TX) into the right internal jugular vein. For adequate oxygenation, the infant required an ECMO flow rate of 360 ml/min (110 ml/kg per minute). After day 10 of ECMO, the infant started showing signs of improvement in oxygenation and the ECMO flow rate was decreased gradually. On day 13 of ECMO, the flow rate was as low as 150 ml/min and a follow-up echocardiogram showed resolution of the pulmonary hypertension. An attempt to wean the infant off ECMO on this day was unsuccessful because of CO 2 retention in the patient. The ECMO circuit was changed because of the presence of clots, and the infant was switched to HFJV while being given ECMO. The infant could then be weaned off veno-venous bypass after 435 hours (18.1 days) of the ECMO run. He was extubated 4 days later. A post-ECMO, computerized tomography scan of the head was normal except for mild extra-axial fluid. Predischarge neurologic examination and hearing screening were normal. He was discharged home on hospital day 58 with administration of nasal cannula oxygen (0.1 l/min). 
Discussion
PPHN associated with cystic adenomatoid malformation of the lung following lobectomy is an uncommon but well known entity. 2 The development of PPHN in infants with CCAM probably has the same pathophysiology as seen with congenital diaphragmatic hernia (CDH). The main pathophysiologic mechanism of PPHN in these two conditions is related to development of pulmonary hypoplasia following the mass effect in the chest during fetal life.
3 Pulmonary hypertension is produced primarily by the reduced size and number of the pulmonary arteries as a result of lung hypoplasia. Further contributions to PPHN are made by increased muscularization of the pulmonary arteries and increased reactivity of the pulmonary vascular bed to vasoconstrictive stimuli such as hypoxia, acidosis, and hypercarbia. 4 The degree of severity of these key physiologic abnormalities may account for the variable responses that infants with CCAM and CDH demonstrate to the conventional treatment for PPHN, which includes high frequency ventilation, induced alkalosis, high inspired oxygen, vasodilators, sedation, and paralysis. They may also account for the overall lower survival rate of 60% in infants with CDH treated with ECMO compared with other conditions, although a survival rate as high as 86% has been reported. 5, 6 Although pulmonary hypoplasia is not reversible, the vascular remodeling and reactivity appear to be amenable to "lung rest" associated with ECMO therapy in infants with CDH. It has been suggested that delayed operation with preoperative stabilization in infants with CDH may help prevent the intense pulmonary vascular reactivity and may contribute to an improved overall survival. The overall survival rate associated with delayed surgical repair and ECMO is reported to be 80%. 7 It is appealing to think that a similar approach in infants with CCAM may improve outcome. However, it is important to remember that other factors may play a role in the outcome of patients with CCAM. The prognosis in infants with CCAM may be determined by the type of lesion and the presence of other comorbid conditions and associated anomalies. According to the Stocker classification, 8 there are three different types of CCAM: Type I, which accounts for about 50% of the cases and presents as single or multiple large cysts (Ͼ2 cm in diameter), is usually associated with a good prognosis and spontaneous resolution during gestation has also been reported. 8, 9 Type II accounts for 40% of the cases and morphologically consists of multiple small cysts (Ͻ1 cm in diameter) intermediate in size between types I and III. Type II is associated with a high incidence of congenital malformations (26%) and carries a poor prognosis. 8, 10 Type III accounts for only 10% of the cases and presents as a large, firm, and solid mass made up of numerous microcysts (each Ͻ0.5 cm in diameter). Type III lesions also carry a poor prognosis. 8 The presence of polyhydramnios, mediastinal shift with compression of the adjacent lung, pulmonary hypoplasia, the involvement of more than one lobe, the type and size of the lesions, and the presence of associated congenital anomalies are all considered poor prognostic indicators. 8, 11 In the current case reported, the infant had several of the poor prognostic indicators (polyhydramnios, mediastinal shift, pulmonary hypoplasia, involvement of more than one lobe, and type II lesion).
The status of this infant with CCAM treated with ECMO is analogous to infants with CDH. The infant demonstrated a "honeymoon period" after lobectomy, followed by an acute deterioration and the development of PPHN meeting ECMO criteria. Inhaled nitric oxide (INO) has emerged as a new therapy in the treatment of PPHN. As regards INO use in CDH, the Neonatal Inhaled Nitric Oxide Study Group (NINOS) 12 concluded that, although INO produced short-term improvements in oxygenation, it failed to reduce the need for ECMO. For INO therapy to be efficacious in the treatment of PPHN, lung recruitment and the establishment of adequate lung volumes are essential. 13, 14 Karamanoukian et al. 13 reported that neonates with lung hypoplasia caused by CDH, who demonstrated lack of a beneficial response to early INO therapy initially, later showed an improved response to INO treatment after surgical repair and ECMO therapy. They attributed this change in response to improvement in lung volumes. Therefore, we can speculate that INO therapy may have a place in the management of PPHN in infants with CCAM, but it may not reduce the need for ECMO.
ECMO is an important adjunctive therapy for severe PPHN in neonates with CCAM after resection. ECMO supports a patient with PPHN until increased pulmonary vascular reactivity resolves, and, if the ECMO run is long enough, it may allow time for pulmonary vascular remodeling to resolve and thereby, improve survival. The duration on ECMO in this case was 435 hours. The optimism to extend ECMO therapy to 10 days and beyond was based on clinical information and literature support of three cases of CCAM treated with extended ECMO and having an overall good outcome. Prior to ECMO, the infant demonstrated good oxygenation, despite oxygen lability, lending support to a case of reversible PPHN most likely secondary to increased pulmonary vascular resistance. The only aspect of uncertainty in this case was the degree of severity and relative contribution of pulmonary hypoplasia to PPHN. As of January 1997, 17 cases of CCAM treated with ECMO had been reported in the Neonatal ECMO Registry. The duration of ECMO was greater than 400 hours in three cases, one of whom died. The overall survival rate was 82%. 15 In the current case reported, prolongation on ECMO was a result of delayed resolution of PPHN and CO 2 retention. Pulmonary hypoplasia was thought to play a significant role in this case. Even with resolution of PPHN, the infant could not be weaned from ECMO because of CO 2 retention thought to be secondary to ventilation-perfusion (V/Q) mismatch. Normalization of PaCO 2 and the ability to wean the infant from ECMO was possible only after the use of HFJV.
One could debate the use of HFJV versus high-frequency oscillatory ventilation as adjunctive therapy in this case, because both are equally effective in removing CO 2 . HFJV was used in this case for the treatment of hypercarbia developed before and after surgery for CCAM, and again to wean the infant off ECMO. For the primary purpose of treating PPHN, it is not clear at this time that HFJV has an advantage over high-frequency oscillatory ventilation. A study by Paranka et al. 16 has shown that neonates with PPHN associated with CDH/lung hyp-oplasia are less likely to respond to HFOV than neonates with respiratory distress syndrome and pneumonia. 16 Our case suggests that pulmonary hypoplasia of the compressed lung is an important consideration in infants with CCAM who develop PPHN after lobectomy. The inability to wean from ECMO may depend on the degree of severity of pulmonary hypoplasia. Although pulmonary hypoplasia is not reversible, the vascular remodeling and reactivity appear to resolve with ECMO therapy. Delayed surgical repair and preoperative stabilization on ECMO may improve outcome in a manner similar to infants with CDH. 2, 7 Further investigation is needed to determine the best management strategy.
